6,205 Shares of Charles River Laboratories International, Inc. $CRL Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 6,205 shares of the medical research company’s stock, valued at approximately $1,831,000.

Several other institutional investors have also made changes to their positions in CRL. Physician Wealth Advisors Inc. increased its holdings in Charles River Laboratories International by 127.9% in the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock worth $29,000 after buying an additional 55 shares during the last quarter. Continuum Advisory LLC acquired a new stake in Charles River Laboratories International in the second quarter valued at approximately $30,000. IFP Advisors Inc lifted its stake in Charles River Laboratories International by 182.8% in the third quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 106 shares during the last quarter. Compass Wealth Management LLC bought a new stake in Charles River Laboratories International in the third quarter worth approximately $69,000. Finally, Activest Wealth Management grew its position in Charles River Laboratories International by 25.9% in the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after acquiring an additional 57 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CRL has been the topic of a number of recent research reports. Zacks Research downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a report on Monday, November 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Deutsche Bank increased their target price on shares of Charles River Laboratories International from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, September 25th. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a report on Monday, August 10th. Finally, UBS Group boosted their price target on Charles River Laboratories International from $357.00 to $387.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Thirteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $308.17.

Charles River Laboratories International Stock Down 0.9%

NYSE CRL opened at $342.81 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.12 and a current ratio of 1.41. The firm has a 50-day simple moving average of $309.32 and a 200 day simple moving average of $227.05. Charles River Laboratories International, Inc. has a twelve month low of $146.20 and a twelve month high of $379.63. The stock has a market cap of $16.43 billion, a PE ratio of 376.71, a PEG ratio of 3.13 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.12. The firm had revenue of $982.73 million for the quarter, compared to analyst estimates of $960.36 million. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The company’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.43 earnings per share. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 11.45 EPS for the current year.

Insider Transactions at Charles River Laboratories International

In related news, Director Nancy C. Andrews sold 573 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the transaction, the director directly owned 1,438 shares of the company’s stock, valued at $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James Foster sold 24,042 shares of the firm’s stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $350.00, for a total value of $8,414,700.00. Following the completion of the transaction, the director directly owned 31,596 shares of the company’s stock, valued at approximately $11,058,600. This trade represents a 43.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 63,352 shares of company stock valued at $20,291,281. 1.30% of the stock is owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.